Lv3
398 积分 2024-08-23 加入
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
12天前
已完结
Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse events
20天前
已完结
Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
29天前
已完结
2024年中国分地区恶性肿瘤流行情况分析
1个月前
已完结
Proteomic and metabolomic profiling of plasma predicts immune-related adverse events in older patients with advanced non-small cell lung cancer
1个月前
已完结
Development and Validation of the Rating of CKD Knowledge Among Older Adults (Know-CKD) With Kidney Failure
1个月前
已关闭
布地奈德福莫特罗粉吸入治疗肺癌合并慢阻肺患者的临床疗效及对患者生活质量的影响
2个月前
已完结
儿童过敏性肺炎的诊治及研究进展
3个月前
已完结
First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study
5个月前
已完结
肺癌与慢性阻塞性肺疾病共病的临床诊疗浅析
7个月前
已完结
皖公网安备34019202002308
